Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

Best cost-effectiveness and worker productivity with initial triple DMARD therapy compared with methotrexate monotherapy in early rheumatoid arthritis: cost-utility analysis of the tREACH trial.

de Jong PH, Hazes JM, Buisman LR, Barendregt PJ, van Zeben D, van der Lubbe PA, Gerards AH, de Jager MH, de Sonnaville PB, Grillet BA, Luime JJ, Weel AE.

Rheumatology (Oxford). 2016 Dec;55(12):2138-2147. Epub 2016 Aug 30.

PMID:
27581208
2.

Long-Term Outcomes of Patients With Recent-Onset Rheumatoid Arthritis After 10 Years of Tight Controlled Treatment: A Randomized Trial.

Markusse IM, Akdemir G, Dirven L, Goekoop-Ruiterman YP, van Groenendael JH, Han KH, Molenaar TH, Le Cessie S, Lems WF, van der Lubbe PA, Kerstens PJ, Peeters AJ, Ronday HK, de Sonnaville PB, Speyer I, Stijnen T, Ten Wolde S, Huizinga TW, Allaart CF.

Ann Intern Med. 2016 Apr 19;164(8):523-31. doi: 10.7326/M15-0919. Epub 2016 Mar 1.

PMID:
27089068
3.

Feasibility of tailored treatment based on risk stratification in patients with early rheumatoid arthritis.

Markusse IM, de Vries-Bouwstra JK, Han KH, van der Lubbe PA, Schouffoer AA, Kerstens PJ, Lems WF, Huizinga TW, Allaart CF.

Arthritis Res Ther. 2014 Sep 25;16(5):430. doi: 10.1186/s13075-014-0430-3.

4.

Randomised comparison of initial triple DMARD therapy with methotrexate monotherapy in combination with low-dose glucocorticoid bridging therapy; 1-year data of the tREACH trial.

de Jong PH, Hazes JM, Han HK, Huisman M, van Zeben D, van der Lubbe PA, Gerards AH, van Schaeybroeck B, de Sonnaville PB, van Krugten MV, Luime JJ, Weel AE.

Ann Rheum Dis. 2014 Jul;73(7):1331-9. doi: 10.1136/annrheumdis-2013-204788. Epub 2014 May 1.

5.

Association of low baseline levels of erythrocyte folate with treatment nonresponse at three months in rheumatoid arthritis patients receiving methotrexate.

de Rotte MC, de Jong PH, Pluijm SM, Calasan MB, Barendregt PJ, van Zeben D, van der Lubbe PA, de Sonnaville PB, Lindemans J, Hazes JM, de Jonge R.

Arthritis Rheum. 2013 Nov;65(11):2803-13. doi: 10.1002/art.38113.

6.

Induction therapy with a combination of DMARDs is better than methotrexate monotherapy: first results of the tREACH trial.

de Jong PH, Hazes JM, Barendregt PJ, Huisman M, van Zeben D, van der Lubbe PA, Gerards AH, de Jager MH, de Sonnaville PB, Grillet BA, Luime JJ, Weel AE.

Ann Rheum Dis. 2013 Jan;72(1):72-8. doi: 10.1136/annrheumdis-2011-201162. Epub 2012 Jun 7.

PMID:
22679301
7.

Treatment decisions and related costs differ significantly depending on the choice of a disease activity index in RA, according to 1987 and 2010 classification criteria.

de Jong PH, Hazes JM, van Zeben D, van der Lubbe PA, de Jager MH, de Sonnaville PB, Luime JJ, Weel AE.

Rheumatology (Oxford). 2012 Jul;51(7):1269-77. doi: 10.1093/rheumatology/kes008. Epub 2012 Feb 29.

PMID:
22378716
8.

A decrease in disease activity score (DAS) level is associated with a decrease in health assessment questionnaire (HAQ) score, independent of follow-up duration, during 5 years of tightly controlled treatment: results from the BeSt study.

van der Kooi E, Klarenbeek NB, Güler-Yüksel M, Kerstens PJ, van der Lubbe PA, Westedt ML, ten Wolde S, Huizinga TW, Dijkmans BA, Allaart CF.

Ann Rheum Dis. 2011 Jan;70(1):168-71. doi: 10.1136/ard.2010.133132. Epub 2010 Nov 29.

PMID:
21115551
9.

Drug-free remission, functioning and radiographic damage after 4 years of response-driven treatment in patients with recent-onset rheumatoid arthritis.

van der Kooij SM, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Güler-Yüksel M, Zwinderman AH, Kerstens PJ, van der Lubbe PA, de Beus WM, Grillet BA, Ronday HK, Huizinga TW, Breedveld FC, Dijkmans BA, Allaart CF.

Ann Rheum Dis. 2009 Jun;68(6):914-21. doi: 10.1136/ard.2008.092254. Epub 2008 Jul 28.

PMID:
18662933
10.

Patient preferences for treatment: report from a randomised comparison of treatment strategies in early rheumatoid arthritis (BeSt trial).

Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, Kerstens PJ, Grillet BA, de Jager MH, Han KH, Speyer I, van der Lubbe PA, Seys PE, Breedveld FC, Dijkmans BA.

Ann Rheum Dis. 2007 Sep;66(9):1227-32. Epub 2007 Apr 3.

11.

Catastrophic manifestation of the antiphospholipid syndrome.

Schaar CG, Ronday KH, Boets EP, van der Lubbe PA, Breedveld FC.

J Rheumatol. 1999 Oct;26(10):2261-4.

PMID:
10529152
12.

Flexion contractures associated with a malignant neoplasm: 'A paraneoplastic syndrome?'.

Eekhoff EM, van der Lubbe PA, Breedveld FC.

Clin Rheumatol. 1998;17(2):157-9.

PMID:
9641516
13.

Treatment with a chimeric CD4 monoclonal antibody is associated with a relative loss of CD4+/CD45RA+ cells in patients with rheumatoid arthritis.

van der Lubbe PA, Breedveld FC, Tak PP, Schantz A, Woody J, Miltenburg AM.

J Autoimmun. 1997 Feb;10(1):87-97.

PMID:
9080303
14.

Reduction of synovial inflammation after anti-CD4 monoclonal antibody treatment in early rheumatoid arthritis.

Tak PP, van der Lubbe PA, Cauli A, Daha MR, Smeets TJ, Kluin PM, Meinders AE, Yanni G, Panayi GS, Breedveld FC.

Arthritis Rheum. 1995 Oct;38(10):1457-65.

PMID:
7575695
15.

A randomized, double-blind, placebo-controlled study of CD4 monoclonal antibody therapy in early rheumatoid arthritis.

van der Lubbe PA, Dijkmans BA, Markusse HM, Nässander U, Breedveld FC.

Arthritis Rheum. 1995 Aug;38(8):1097-106.

PMID:
7639806
16.

Monoclonal antibody therapy of inflammatory rheumatic diseases.

Breedveld FC, van der Lubbe PA.

Br Med Bull. 1995 Apr;51(2):493-502. Review.

PMID:
7552078
17.

Treatment of rheumatoid arthritis with a chimeric CD4 monoclonal antibody (cM-T412): immunopharmacological aspects and mechanisms of action.

van der Lubbe PA, Reiter C, Miltenburg AM, Krüger K, de Ruyter AN, Rieber EP, Bijl JA, Riethmüller G, Breedveld FC.

Scand J Immunol. 1994 Mar;39(3):286-94.

PMID:
8128188
18.

Chimeric CD4 monoclonal antibody cM-T412 as a therapeutic approach to rheumatoid arthritis.

van der Lubbe PA, Reiter C, Breedveld FC, Krüger K, Schattenkirchner M, Sanders ME, Riethmüller G.

Arthritis Rheum. 1993 Oct;36(10):1375-9.

PMID:
8216397
19.

Anti-CD4 therapy in rheumatoid arthritis.

van der Lubbe PA, Reiter C, Riethmüller G, Breedveld FC.

Clin Exp Rheumatol. 1993 Mar-Apr;11 Suppl 8:S151. No abstract available.

PMID:
8324941
20.

99mTc human immunoglobulin scintigraphy--a reliable method to detect joint activity in rheumatoid arthritis.

de Bois MH, Arndt JW, van der Velde EA, van der Lubbe PA, Westedt ML, Pauwels EK, Breedveld FC.

J Rheumatol. 1992 Sep;19(9):1371-6.

PMID:
1433003
21.

Anti-CD4 monoclonal antibody for relapsing polychondritis.

van der Lubbe PA, Miltenburg AM, Breedveld FC.

Lancet. 1991 Jun 1;337(8753):1349. No abstract available.

PMID:
1674322
22.

Measurement of synovial inflammation in rheumatoid arthritis with technetium 99m labelled human polyclonal immunoglobulin G.

van der Lubbe PA, Arndt JW, Calame W, Ferreira TC, Pauwels EK, Breedveld FC.

Eur J Nucl Med. 1991;18(2):119-23.

PMID:
2044570

Supplemental Content

Loading ...
Support Center